Naprosyn: profile and news

Helsinn and Therabel Pharma Announce a License Agreement for Aloxi ... Feb 7, 2006
...with THERABEL PHARMA under which it granted THERABEL PHARMA the exclusive License and Distribution rights to distribute, market and sell Aloxi(R) (palonosetron ... - PR Newswire UK (press release),

Helsinn and Biovitrum Enter a License Agreement for Nordic ... Feb 15, 2006
...and Biovitrum AB, Sweden announce the signing of an agreement granting Biovitrum the exclusive license and distribution rights of Aloxi(R) (Palonosetron ... - Genetic Engineering News,

Helsinn and Biovitrum enter a license agreement for Nordic ... Feb 16, 2006
AB, Sweden announce the signing of an agreement granting Biovitrum the exclusive license and distribution rights of Aloxi® (Palonosetron hydrochloride) in the ... - WebWire (press release),

Helsinn and Biovitrum Enter a License Agreement for Nordic ... Feb 15, 2006
Swedish Biotechnology company, announce the signing of an agreement granting Biovitrum the exclusive License and Distribution rights of Aloxi(R) (Palonosetron ... - PR Newswire UK (press release),

CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and ... Feb 9, 2006
...and acute care-focused biopharmaceutical company, today announced that total revenue for 2005 increased 43% to $279.4 million, including Aloxi(R) (palonosetron ... - Genetic Engineering News,

ΞΕ�?Η ΔΗΜΟΣΙΕΥΣΗ-Α�?ΑΚΟΙ�?ΩΣΗ ΤΥΠΟΥ-PRN ... Feb 15, 2006
Aloxi(r) is a strong and long-lasting antiemetic belonging to the second generation of serotonin (5-HT3) antagonists, the leading class for the prevention of ... - Athens News Agency,

ΞΕ�?Η ΔΗΜΟΣΙΕΥΣΗ-Α�?ΑΚΟΙ�?ΩΣΗ ΤΥΠΟΥ-PRN ... Feb 9, 2006
...which it granted THERABEL PHARMA the exclusive License and Distribution rights to distribute, market and sell Aloxi(R) (palonosetron hydrochloride) in France ... - Athens News Agency,

MGI PHARMA To Present at the Lehman Brothers 9th Annual Global ... Mar 3, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Genetic Engineering News,

Biovitrum to Distribute Helsinn's Antiemetic in Nordic Territories Feb 17, 2006
Sweden's Biovitrum has agreed to distribute Aloxi, Helsinn Healthcare's drug designed to prevent nausea and vomiting induced by chemotherapy, in the Nordic ... - International News Service,

CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and ... Feb 9, 2006
...and acutecare-focused biopharmaceutical company, today announced that totalrevenue for 2005 increased 43% to $279.4 million, including Aloxi(R)(palonosetron ... - Finanzen.net,

MGI Pharma Misses Targets Feb 8, 2006
US sales of the company's Aloxi injection for cancer-related nausea totaled $67 million vs. $56 million in the fourth quarter of the prior year. ... - TheStreet.com

(PRN) - LIMS Uptake on the Rise in Eastern Europe ... [+] Feb 8, 2006
...[+]. (PRN) - Helsinn and Therabel Pharma Announce a License Agreement for Aloxi(R) ... [. PRN) - We Think Dad Knows Best But is He Good With Money? ... [. ... - Bolsamania.com,

(PRN) - AU Optronics Reports 4Q2005 Results ... [+] Feb 7, 2006
...[+]. (PRN) - Helsinn and Therabel Pharma Announce a License Agreement for Aloxi(R) ... [. PRN) - Advanced Semiconductor Engineering, Inc. ... - Bolsamania.com,

Consiga la Gold Card American Express ahora Feb 8, 2006
...[+]. (PRN) - Helsinn and Therabel Pharma Announce a License Agreement for Aloxi(R) ... [. PRN) - We Think Dad Knows Best But is He Good With Money? ... [. ... - Bolsamania.com,

MGI PHARMA to Present at the BIO CEO and Investor Conference Feb 7, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Genetic Engineering News,

MGI PHARMA to Present at the BIO CEO and Investor Conference Feb 7, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride)injection and Gliadel(R) Wafer (polifeprosan 20 with carmustineimplant) in the United States. ... - Finanzen.net,

AP Pharma seeks approval for trial protocol Jan 25, 2006
The proposed trial will compare the safety and efficacy of APF530 with MGI Pharma's Aloxi (palonosetron) for the treatment of acute and delayed chemotherapy ... - Pharmaceutical Business Review

MGI Sees 2006 Sales Below Wall Street View Jan 10, 2006
MINNEAPOLIS (AP) - MGI Pharma Inc. on Tuesday said sales of its key Aloxi drug missed company guidance and predicted 2006 sales beneath Wall Street views. ... - MSN Money

NWA gets extension to file reorganization plan Jan 11, 2006
Bloomington-based MGI Pharma said Tuesday that sales of its Aloxi drug missed company guidance and predicted 2006 sales beneath Wall Street views. ... - Pioneer Press,

MGI sees 2006 sales below Wall Street view Jan 10, 2006
JAN. 10 1:19 PM ET MGI Pharma Inc. on Tuesday said sales of its key Aloxi drug missed company guidance and predicted 2006 sales beneath Wall Street views. ... - BusinessWeek

MGI Pharma Still A 'Solid Company' Despite Mixed Guidance Jan 11, 2006
MGI Pharma (nasdaq: MOGN - news - people ) to $24 from $30 after the company pre-announced slightly lower-than-expected fourth-quarter sales of Aloxi, its post ... - Forbes

UPDATE 1-MGI Pharma 2006 revenue outlook below expectations Jan 10, 2006
Unaudited figures showed that sales of Aloxi, the company's treatment for chemotherapy-induced nausea and vomiting, rose 56 percent in 2005 to $248 million ... - Reuters

MGI Pharma provides '06 sales guidance Jan 10, 2006
Sales of the company's Aloxi injection, a nausea drug, increased 56 percent to $248 million in 2005, including $67 million in the fourth quarter. ... - Twin Cities Business Journal,

MGI Pharma "buy," target price reduced Jan 12, 2006
In a research note published yesterday, the analyst mentions that the company has recently pre-announced its sales results for Aloxi and Giladel below the ... - New Ratings

Public company news Jan 15, 2006
MGI Pharma (Nasdaq: MOGN): Said 2005 sales of its Aloxi drug — an injection to treat chemotherapy-related nausea — totaled $248 million, below MGI's ... - Pioneer Press,

AP Pharma Announces Submission of APF530 Pivotal Trial Protocol ... Jan 24, 2006
The proposed trial will compare the safety and efficacy of APF530 with palonosetron (brand name ALOXI(R)) for the treatment of acute and delayed chemotherapy ... - Business Wire (press release),

MGI Pharma Seen Meeting 2005 Guidance For Aloxi Nov 29, 2005
Prudential Equity Group said MGI Pharma (nasdaq: MOGN - news - people ) will likely meet 2005 sales goals for Aloxi despite weak monthly sales released today ... - Forbes

Biotechs Take A Beating Dec 3, 2005
MGI Pharma (nasdaq: MOGN - news - people ) fell 8.7% for the week after monthly sales data for cancer pain treatment Aloxi came in weaker than expected. ... - Forbes

MGI PHARMA Announces Expiration of Tender Offer for Guilford ... Nov 29, 2005
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Business Wire (press release),

GSW Worldwide to Lead SaforisTM Launch Campaign for MGI PHARMA ... Nov 14, 2005
MGI PHARMA markets Aloxi ® (palonosetron hydrochloride) injection and Gliadel ® Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com (press release),

MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals Oct 3, 2005
...transaction enhances MGI PHARMA's late-stage acute care development pipeline by adding Aquavan(R) Injection, a complementary product to Aloxi(R) injection for ... - Genetic Engineering News,

MGI Pharma "outperform," target price reduced Oct 5, 2005
The healthy sales of MGI Pharma's Aloxi drug and the expected launch of Dacogen in early-2006 would drive the company's stock performance going forward, Robert ... - New Ratings

MGI Pharma completes acquisition of Guilford Pharmaceuticals Oct 4, 2005
...transaction enhances MGI Pharma's late-stage acute care development pipeline by adding Aquavan Injection, a complementary product to Aloxi injection for PONV ... - Pharmaceutical Business Review

MGI Pharma completes Guilford deal Oct 4, 2005
...target the acute-care market. MGI Pharma's leading product is the anti-nausea drug Aloxi. Guilford's pipeline includes two cancer ... - Bizjournals.com,

MGI Pharma Shares Offer 'Very Good Buying Opportunity' Sep 28, 2005
Group maintained an "overweight" rating on MGI Pharma (nasdaq: MOGN - news - people ) after the drug company tightened sales guidance for Aloxi, a cancer pain ... - Forbes

Company news Sep 27, 2005
MGI Pharma Inc., Bloomington, revised its projection of sales for Aloxi, its antinausea drug. ... In July it expected Aloxi sales of $260 million for 2005. ... - Minneapolis Star Tribune (subscription),

MGI Closes Guilford Deal, Updates Outlook Oct 3, 2005
MGI projected sales of Aloxi -- its drug for chemotherapy-induced nausea -- will range from $250 million to $260 million, indicating sales could fall below the ... - MSN Money

MGI Pharma "outperform," estimates reduced Sep 28, 2005
In a research note published this morning, the analysts mention that the company has reduced its FY05 sales guidance for Aloxi from $260 million to $250-$260 ... - New Ratings

MGI Pharma downgraded to "market perform" - update Sep 28, 2005
In a research note published this morning, the analysts mention that the FY05 sales estimate for Aloxi has been reduced from $260 million to $250 million. ... - New Ratings

Guilford Pharmaceuticals Stockholders Vote to Approve MGI PHARMA ... Sep 29, 2005
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), and Kadian(R) (sustained ... - PR Newswire (press release),

Guilford Pharmaceuticals Stockholders Vote to Approve MGI PHARMA ... Sep 29, 2005
MGI PHARMA markets Aloxi® (palonosetron hydrochloride) injection, Gliadel® wafer (polifeprosan 20 with carmustine implant), and Kadian® (sustained release ... - Yahoo! News (press release)

MGI PHARMA to Present at the UBS 2005 Global Life Sciences ... Sep 20, 2005
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine ... - PharmaLive.com (press release),

Coffee with: Ray Frost Sep 11, 2005
...profit this past year. They're oncology-focused. They have a drug called Aloxi. It's the hottest drug in its class. There's not a ... - Minneapolis Star Tribune (subscription),